Trial Profile
A Phase 1, Randomized, Open-label, Cross-over, Single-day Study Of Pf-04937319 To Characterize Relative Bioavailability, Tolerability, And Pharmacodynamics Of Four Oral Formulations In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs PB 201 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 15 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov
- 18 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov